Find a Provider

Steven M. Albelda, MD

Steven M. Albelda, MD Physician

Vice Chief and Director, Lung Research, Pulmonary and Critical Care Medicine
William Maul Measey Professor of Medicine

Dr. Albelda is a Penn Medicine employed physician.

Clinical Specialties


  • Medicine
    • Pulmonary Medicine

Programs & Services:

  • Cancer
    • Lung Cancer
    • Mesothelioma
  • Lung
    • Medical Critical Care
    • Mesothelioma & Pleural Disease

Board Certification:

  • Pulmonary Disease, 1984

Conditions & Treatments:

  • gene therapy
  • Lung Cancer
  • Lung Carcinoid Tumor
  • Mesothelioma
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer

Practice Locations and Appointments

  • Harron Lung Center

    Perelman Center for Advanced Medicine West Pavilion, 1st Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American Society for Clinical Investigation, National American Society of Gene Therapy, 2004-2008 Committee Member, Cancer Gene Therapy Committee, National American Thoracic Society, National Laenec Society of Pulmonary Physicians, Local Member of Executive Committee, International Mesothelioma Interest Group, International National Cancer Institute: Ad Hoc Study Reviewer: Cancer Therapeutics, National National Cancer Institute: Ad Hoc Study Reviewer: Cancer Therapeutics, National Sigma Xi, Research Society of North America, Associate Member, National


Dr. Albelda is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Research Interests:

Immuno-gene Therapy for Thoracic Malignancies
Lung cancer and other thoracic malignancies are the leading cause of cancer deaths in the United States today. The Thoracic Oncology Research Laboratory is focusing on the design of new treatment strategies for lung cancer and mesothelioma based on the rapidly evolving disciplines of molecular biology, immunotherapy, and gene therapy.
Dr. Albelda’s research is translational in focus and includes animal models, work with human tumor samples, and the conduct of clinical trials. This work is primarily funded through a recently renewed Program Project from the National Cancer Institute and participation in a number of RO1 grants.
The tumor microenvironment is one area of active study. Studies are underway with the goals of 1) a better understanding of the biology of the tumor microenvironment with a focus on the immunuosuppressive activities of white blood cells and fibroblasts, 2) novel approaches to alter the tumor microenvironment to enhance immunotherapy including studying effects using COX-2 inhibitors, TGFbeta inhibitors, T-regulatory cell inhibitors., antibodies against B-cells, and chemotherapeutic drugs. A second area of interest in the lab is the use of adoptive T cell transfer to treat lung malignancies. Studies are underway to modify T cells in order to make them traffic more efficiently into tumors, to have better killing function, and to resist inactivation by the tumor microenvironment. A T cells targeting cancer-associated fibroblasts is being developed. In addition, Dr. Albelda is closely involved with a number of immunogene clinical trials at Penn using an adenovirus expressing the immune-activator interferon-alpha that is instilled into the pleural space of mesothelioma patients (in collaboration with Dr. Daniel Sterman) and T cells altered to attack the mesothelioma tumor target, mesothelin (in collaboration with Drs. Carl June and Andrew Haas).

Selected Publications:

David Holt, Olugbenga Okusanya, Ryan Judy, Ollin Venegas, Jack Jiang, Elizabeth De Jesus, Evgeniy Eruslanov, Jon Quatromoni, Pratik Bhojnagarwala, Charuhas Deshpande, Steven Albelda, Shuming Nie, Sunil Singhal: Intraoperative Near-Infrared Imaging Can Distinguish Cancer from Normal Tissue but Not Inflammation PLOS One 9 (7): e103342,2014.

Moon EK1, Wang LC2, Dolfi DV3, Wilson CB4, Ranganathan R2, Sun J2, Kapoor V2, Scholler J4, Puré E5, Milone MC4, June CH4, Riley JL3, Wherry EJ3, Albelda SM2.: Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors. Clinical Cancer Research 20 (16): 1-12,2014.

Quatromoni JG, Singhal S, Bhojnagarwala P, Hancock WW, Albelda SM, Eruslanov E.: An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. Journal of Leukocyte Biology : 2014.

Schwed Lustgarten Daniel E, Thompson Jeffrey, Yu Gordon, Vachani Anil, Vaidya Bhavesh, Rao Chandra, Connelly Mark, Udine Michelle, Tan Kay See, Heitjan Daniel F, Albelda Steven: Use of Circulating Tumor Cell Technology (CELLSEARCH®) for the Diagnosis of Malignant Pleural Effusions. Annals of the American Thoracic Society : 2013.

Baek Kwan-Hyuck, Bhang Dongha, Zaslavsky Alexander, Wang Liang-Chuan, Vachani Anil, Kim Carla F, Albelda Steven M, Evan Gerard I, Ryeom Sandra: Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. The Journal of clinical investigation 123 (10): 4375-89,2013.

Liu Yujie, Wang Liqing, Predina Jarrod, Han Rongxiang, Beier Ulf H, Wang Liang-Chuan S, Kapoor Veena, Bhatti Tricia R, Akimova Tatiana, Singhal Sunil, Brindle Paul K, Cole Philip A, Albelda Steven M, Hancock Wayne W: Inhibition of p300 impairs Foxp3? T regulatory cell function and promotes antitumor immunity. Nature medicine 19 (9): 1173-7,2013.

Stevenson James P, Kindler Hedy L, Papasavvas Emmanouil, Sun Jing, Jacobs-Small Mona, Hull Jennifer, Schwed Daniel, Ranganathan Anjana, Newick Kheng, Heitjan Daniel F, Langer Corey J, McPherson John M, Montaner Luis J, Albelda Steven M: Immunological effects of the TGFß-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2 (8): e26218,2013.

Quatromoni Jon G, Suzuki Eiji, Okusanya Olugbenga, Judy Brendan F, Bhojnagarwala Pratik, Venegas Ollin, Eruslanov Evgeniy, Predina Jarrod D, Albelda Steven M, Singhal Sunil: The timing of TGF-ß inhibition affects the generation of antigen-specific CD8+ T cells. BMC immunology 14 : 30,2013.

Marcela V. Maus, Andrew R. Haas, Gregory L. Beatty, Steven M. Albelda, Bruce L. Levine, Xiaojun Liu, Yangbing Zhao, Michael Kalos, and Carl H. June: T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans Cancer Immunology Research 1 (1): 26-31,2013.

Riese Matthew J, Wang Liang-Chuan S, Moon Edmund K, Joshi Rohan P, Ranganathan Anjana, June Carl H, Koretzky Gary A, Albelda Steven M: Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer research 73 (12): 3566-77,2013.

View all publications

Academic Contact Info

1016B Abramson Research Center
3615 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 573-9933
Fax: (215) 573-4469
Patient appointments: 800-789-PENN (7366)

Related Links